Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongyang Xuanbi pillulas is a Traditional Chinese Medicine (TCM) formulation developed by the Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine. It is specifically indicated for the treatment of chest pain associated with gastroesophageal reflux disease (GERD) in patients presenting with the TCM syndrome of hypofunction of Yang Qi in the chest. The formulation is designed to 'unblock Yang' and 'disseminate painful obstruction' (Xuanbi), addressing the underlying TCM pathology of chest Bi. In clinical trials, it is evaluated as a combination therapy alongside proton pump inhibitors like rabeprazole to improve clinical outcomes and symptom relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongyang Xuanbi pillulas.